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Background
Elevated lipoprotein-associated phospholipase A2 activity promotes the develop-
ment of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme 
are associated with an increased risk of coronary events. Darapladib is a selective 
oral inhibitor of lipoprotein-associated phospholipase A2.
Methods
In a double-blind trial, we randomly assigned 15,828 patients with stable coronary 
heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. 
The primary end point was a composite of cardiovascular death, myocardial infarc-
tion, or stroke. Secondary end points included the components of the primary end 
point as well as major coronary events (death from coronary heart disease, myocar-
dial infarction, or urgent coronary revascularization for myocardial ischemia) and total 
coronary events (death from coronary heart disease, myocardial infarction, hospital-
ization for unstable angina, or any coronary revascularization).
Results
During a median follow-up period of 3.7 years, the primary end point occurred in 
769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) 
in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence 
interval [CI], 0.85 to 1.03; P = 0.20). There were also no significant between-group 
differences in the rates of the individual components of the primary end point or in 
all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major 
coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P = 0.045) 
and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; 
P = 0.02).
Conclusions
In patients with stable coronary heart disease, darapladib did not significantly re-
duce the risk of the primary composite end point of cardiovascular death, myocardial 
infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov 
number, NCT00799903.)
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A therosclerotic lesions in humans — in particular, vulnerable1 and ruptured plaques — are characterized by inflamma-
tory activity and a high expression of lipoprotein-
associated phospholipase A2.2,3 In atherosclerotic 
plaques, lipoprotein-associated phospholipase A2 
increases the production of proinflammatory and 
proapoptotic mediators.4-8 In a meta-analysis of 
individual records from 79,036 participants in 32 
prospective studies, there was a continuous asso-
ciation between lipoprotein-associated phospho-
lipase A2 activity and the risk of coronary heart 
disease, with a relative increase in risk of 1.10 
(95% confidence interval [CI], 1.05 to 1.16) for 
each 1-SD increase in lipoprotein-associated phos-
pholipase A2 activity, after adjustment for conven-
tional risk factors.9
Darapladib is a potent and reversible oral in-
hibitor of lipoprotein-associated phospholipase 
A2.10 In a swine model of atherosclerosis, dara-
pladib reduced levels of lipoprotein-associated 
phospholipase A2 in plaque, reduced the necrotic 
core area, and inhibited the development of le-
sions in coronary arteries.11 Darapladib has also 
been shown to reduce lipoprotein-associated phos-
pholipase A2 activity in human carotid plaque.12 
In the Integrated Biomarker and Imaging Study 2 
(IBIS-2) involving patients with coronary heart 
disease, darapladib, as compared with placebo, 
halted the progression in the volume of the 
necrotic core of coronary-artery plaques (a second-
ary end point), as determined by intravascular 
ultrasonographic virtual histologic analysis dur-
ing a 12-month period.13 These findings suggest 
that darapladib could reduce the risk of events 
associated with coronary heart disease by alter-
ing the composition of atherosclerotic plaques to 
a less vulnerable state.1 In the Stabilization of 
Atherosclerotic Plaque by Initiation of Darap-
ladib Therapy (STABILITY) trial, we evaluated 
the clinical efficacy and safety of darapladib in 
patients with chronic coronary heart disease.
Me thods
Study Design and Oversight
The study design has been described previously.14 
The trial was sponsored by GlaxoSmithKline. The 
executive and steering committees designed the 
study and supervised its conduct. (A complete list 
of committee members is provided in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.) In each country, the study 
was approved by national regulatory authorities 
and by local ethics committees or institutional 
review boards, according to local regulations.
Data were collected and managed by Glaxo-
SmithKline. Unblinded interim analyses of the 
ongoing trial, including four efficacy analyses 
(two prespecified and two unplanned) and semi-
annual safety analyses, were conducted at the 
University of Wisconsin–Madison and reviewed 
by an independent data and safety monitoring 
committee. The final analyses of trial data were 
performed by GlaxoSmithKline. Final statistical 
analyses of key efficacy and safety measures, 
including those presented in this article, were 
independently verified by the Duke Clinical Re-
search Institute.
The first draft of the manuscript was written 
by the first author. The executive and steering 
committees contributed to subsequent drafts of 
the manuscript and approved the submission of 
the final manuscript for publication. The study’s 
cochairs had full access to all data, verified their 
accuracy, and vouch for the fidelity of the study 
to the protocol, available at NEJM.org.
Study Population
Patients were eligible to participate in the study 
if they had coronary heart disease, as documented 
by at least one of the following: previous myocar-
dial infarction, previous percutaneous coronary 
intervention (PCI) or coronary-artery bypass graft-
ing (CABG), or multivessel coronary artery dis-
ease. In addition, at least one of the following 
additional predictors of cardiovascular risk was 
required: an age of 60 years or older, diabetes 
requiring pharmacotherapy, a high-density lipo-
protein (HDL) cholesterol level of less than 40 mg 
per deciliter (1.03 mmol per liter), status as a 
smoker of five or more cigarettes per day at study 
entry or within 3 months before screening, mod-
erate renal dysfunction, or polyvascular arterial 
disease. Exclusion criteria were planned PCI or 
CABG or another major surgical procedure, cur-
rent liver disease, severe renal impairment, a his-
tory of nephrectomy or kidney transplantation, 
current New York Heart Association class III or 
IV heart failure, or severe asthma that was poorly 
controlled with standard medical therapy. Details 
of the inclusion and exclusion criteria are pro-
vided in the Supplementary Appendix. All patients 
provided written informed consent.
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Study Procedures and Follow-up
After baseline assessments were performed, pa-
tients were randomly assigned, with the use of an 
interactive voice-response system, to receive either 
a once-daily oral dose of darapladib (160 mg) or 
matching placebo to be taken with food and 
swallowed whole. The assigned dose of darap-
ladib was expected to lower plasma levels of lipo-
protein-associated phospholipase A2 by approxi-
mately 60%.13
Patients were instructed to return for clinic 
visits 1, 3, and 6 months after randomization 
and thereafter every 6 months for the duration 
of the study. In addition, patients were followed 
up by telephone beginning at 9 months and then 
every 6 months thereafter until the end of the 
study.
Investigators were strongly encouraged to treat 
patients according to international guidelines 
for secondary prevention of coronary heart dis-
ease. All patients were to receive long-term treat-
ment with platelet-inhibitor therapy and statin 
therapy unless such therapy was not indicated 
according to guidelines, was contraindicated, or 
resulted in unacceptable side effects. Metrics of 
standard of care were monitored by the study 
leaders and provided to all investigators every 
6 months, which allowed the investigators to 
compare the standard of care at their sites with 
national and international standards at other sites 
participating in this study. In addition, the im-
portance of adherence to standard-of-care med-
ications was reinforced over the duration of the 
trial and at periodic meetings with investigators.
Patients were instructed to continue taking 
the study drug until the day before their end-of-
treatment visit. Patients who permanently dis-
continued a study drug before the end of the 
study were contacted by telephone for an assess-
ment of clinical outcomes. At the end of the 
study, all patients were asked to return to the 
clinic within a 3-month period for their final 
study visit. Final survival status was sought for 
patients who were lost to follow-up or withdrew 
consent.
Study End Points
The primary end point was a composite of cardio-
vascular death, myocardial infarction, or stroke. 
Secondary end points included major coronary 
events (a composite of death from coronary heart 
disease, myocardial infarction, or urgent coro-
nary revascularization for myocardial ischemia); 
total coronary events (a composite of death from 
coronary heart disease, myocardial infarction, 
hospitalization for unstable angina, or any coro-
nary revascularization procedure); the individual 
components of the primary end point; a compos-
ite of all-cause mortality, myocardial infarction, 
or stroke; and all-cause mortality. Definitions of 
the primary and secondary end points are pro-
vided in the Supplementary Appendix.
Laboratory Testing
All laboratory tests were performed at central 
laboratories (Quest Diagnostics Clinical Labora-
tories). The estimated glomerular filtration rate 
(GFR) was calculated with the use of the Modifi-
cation of Diet in Renal Disease method.15
Safety Monitoring and Adjudication
Investigators were responsible for detecting, docu-
menting, and reporting adverse events and serious 
adverse events. Information on adverse events 
was collected from the time the randomized reg-
imens were started until 35 days after the last 
dose of a study drug was taken or at the next 
follow-up visit, whichever occurred later. Serious 
adverse events that were assessed as being related 
to a study drug or related to study participation 
were recorded up to and including any follow-up 
contact. The occurrence of cancers and of gastro-
intestinal polyps or neoplasms was recorded 
until the end of the study, including during the 
period after discontinuation of the study drug, 
since 2-year carcinogenicity studies in rodents 
had suggested that darapladib was associated 
with the development of jejunal adenomas or ad-
enocarcinomas in male mice and rats. Other ad-
verse events of special interest included asthma, 
anaphylaxis, diarrhea, and odor-related events, 
because in previous studies,13 darapladib had 
been associated with an unpleasant odor of skin, 
urine, or feces.
Suspected primary and secondary end points 
were evaluated by an independent clinical-events 
committee whose members were unaware of the 
study-group assignments. Gastrointestinal neo-
plasms and cancers were adjudicated by a sepa-
rate committee in a blinded fashion.
Statistical Analysis
We anticipated an annual event rate for the pri-
mary end point of 4% in the placebo group. We 
then estimated that 1500 events would be re-
quired for the study to have a power of 90% to 
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detect a relative-risk reduction of 15.5% in the 
rate of the primary end point in the darapladib 
group, as compared with the placebo group.
All patients who underwent randomization 
were included in the intention-to-treat analyses. 
Time-to-event analyses were performed with the 
use of Kaplan–Meier estimates for the primary 
and secondary end points. Hazard ratios and 
95% confidence intervals were estimated with 
the use of Cox proportional-hazards models. 
The effect of treatment on the primary end 
point was estimated with the use of hazard 
ratios and adjusted 95.1% confidence intervals, 
with a two-sided P value of 0.049 indicating sta-
tistical significance after adjustment for the four 
interim analyses conducted by the data and 
safety monitoring committee. For secondary and 
other end points, no adjustments were made 
for multiple testing. Nominal significance re-
fers to an unadjusted P value of less than 0.05 
in which the type I error was not controlled at 
the 5% level.
The consistency of effects on efficacy end 
points was prespecified to be explored in 35 sub-
groups, without adjustment for multiple com-
parisons. The analyses of safety data focused on 
adverse events, laboratory data, and vital signs 
and included all patients who received at least 
one dose of a study drug. Baseline and on-
treatment lipoprotein-associated phospholipase 
A2 levels are not yet available and thus are not 
reported here.
R esult s
Study Patients
From December 2008 through April 2010, we en-
rolled 15,828 patients at 663 centers in 39 coun-
tries (Fig. 1). A total of 7924 patients were ran-
domly assigned to the darapladib group, and 
7904 were assigned to the placebo group. The 
median age of the patients was 65 years; 81% 
were men, 78% were white, 20% were current or 
recent smokers, and 34% had diabetes mellitus 
requiring pharmacotherapy (Table 1, and Table S1 
in the Supplementary Appendix). The median low-
density lipoprotein (LDL) cholesterol level at base-
line was 79.9 mg per deciliter (2.07 mmol per liter).
Follow-up, Adherence, and Background 
Therapy
The median duration of follow-up for the primary 
end point was 3.7 years (interquartile range, 
3.5 to 3.8). The median duration of study-drug 
exposure was 3.5 years in the darapladib group 
and 3.6 years in the placebo group. We were able 
to ascertain vital status for 99.3% of the patients 
(15,722 of 15,828) and for 99.6% of the total pos-
sible follow-up time. For the analysis of the pri-
mary end point, complete follow-up was obtained 
in 96.5% of patients and for 97.7% of total follow-
up time (Fig. S1 in the Supplementary Appendix). 
The percentage of patients with at least 80% ad-
herence to treatment, as determined on the basis 
of pill counts, was 89.3% in the darapladib group 
and 91.3% in the placebo group.
15,828 Patients underwent randomization
7924 Were assigned to receive
darapladib
7912 Received darapladib
12 Did not receive darapladib
7904 Were assigned to receive
placebo
7890 Received placebo
14 Did not receive placebo
7924 Were included in the analysis
7641 Had known cardiovascular
end-point status at the end
of the study
283 Had unknown cardiovascular
end-point status at the end
of the study
7877 Had known vital status at the
end of the study
47 Had unknown vital status 
at the end of the study
7904 Were included in the analysis
7628 Had known cardiovascular
end-point status at the end
of the study
276 Had unknown cardiovascular
end-point status at the end
of the study
7845 Had known vital status at the
end of the study
59 Had unknown vital status 
at the end of the study
7646 Completed the study
278 Withdrew from the study
175 Withdrew consent
80 Were lost to follow-up
23 Participated at investigative 
site that closed
5322 Were taking darapladib at the
         end of the study
2590 Discontinued darapladib
1569 Had adverse event
47 Had protocol deviation
55 Were lost to follow-up
895 Decided to stop or proxy
       decision
7 Stopped owing to sponsor
   decision
17 Participated at investigative
site that closed
7631 Completed the study
273 Withdrew from the study
179 Withdrew consent
69 Were lost to follow-up
25 Participated at investigative 
site that closed
5774 Were taking placebo at the 
         end of the study
2116 Discontinued placebo
1067 Had adverse event
50 Had protocol deviation
49 Were lost to follow-up
918 Decided to stop or proxy
       decision
13 Stopped owing to sponsor
     decision 
19 Participated at investigative
site that closed
Figure 1. Randomization and Follow-up.
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The use of guideline-recommended treatments 
for secondary prevention was high. At trial close-
out, 90% of the patients were taking aspirin, 
96% statins, 79% beta-blockers, 54% angiotensin-
converting–enzyme inhibitors, and 26% angio-
tensin II–receptor blockers. The median LDL cho-
lesterol level at the end of the study was 78.0 mg 
per deciliter (2.02 mmol per liter) in the darap-
Table 1. Characteristics of the Patients at Baseline.*
Characteristic Placebo (N = 7904) Darapladib (N = 7924)
Age
Median (IQR) — yr 65.0 (59.0–71.0) 65.0 (59.0–71.0)
<65 yr — no. (%) 3893 (49.3) 3808 (48.1)
65–74 yr — no. (%) 2938 (37.2) 3022 (38.1)
≥75 yr — no. (%) 1073 (13.6) 1094 (13.8)
Female sex — no. (%) 1506 (19.1) 1461 (18.4)
Race or ethnic group — no. (%)†
White 6174 (78.1) 6232 (78.6)
Black 191 (2.4) 175 (2.2)
Central, South, or Southeast Asian 598 (7.6) 592 (7.5)
East Asian or Japanese 766 (9.7) 758 (9.6)
Other 175 (2.2) 167 (2.1)
Region of enrollment — no. (%)
North America
All 2016 (25.5) 2007 (25.3)
United States 1555 (19.7) 1547 (19.5)
South America 597 (7.6) 602 (7.6)
Western Europe 1980 (25.1) 2006 (25.3)
Eastern Europe 1764 (22.3) 1767 (22.3)
Asia or Pacific Rim 1547 (19.6) 1542 (19.5)
Cardiovascular risk factors
Diabetes requiring pharmacotherapy — no. (%) 2687 (34.0) 2664 (33.6)
High-density lipoprotein cholesterol
Median (IQR) — mg/dl 44.4 (38.6–52.9) 44.8 (38.6–53.7)
<40 mg/dl — no. (%) 2786 (35.2) 2646 (33.4)
Smoker — no. (%)‡ 1656 (21.0) 1572 (19.8)
Renal dysfunction — no. (%)§ 2374 (30.0) 2410 (30.4)
Polyvascular disease — no. (%) 1187 (15.0) 1185 (15.0)
Qualifying diagnosis of coronary heart disease — no. (%)
Previous myocardial infarction 4642 (58.7) 4681 (59.1)
Previous coronary revascularization 5911 (74.8) 5952 (75.1)
Percutaneous coronary intervention 3978 (50.3) 3987 (50.3)
Coronary-artery bypass grafting 2592 (32.8) 2644 (33.4)
Multivessel disease 1191 (15.1) 1199 (15.1)
* There was no significant difference between the two groups, except among patients who had a high-density lipoprotein 
cholesterol level of less than 40 mg per deciliter (P = 0.01). Percentages may not total 100 because of rounding. To convert 
the values for cholesterol to millimoles per liter, multiply by 0.02586. IQR denotes interquartile range.
† Race or ethnic group was self-reported.
‡ Smokers included both current smokers of five or more cigarettes per day and those who were smokers within 3 months 
before screening.
§ Renal dysfunction was defined as an estimated glomerular filtration rate of 30 to 59 ml per minute per 1.73 m2 of body-
surface area (moderate kidney disease) or a urine albumin-to-creatinine ratio of 30 or more (as measured in milligrams of 
albumin and grams of creatinine).
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on October 7, 2016. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Dar apladib in Stable Coronary Heart Disease
n engl j med 370;18 nejm.org may 1, 2014 1707
ladib group and 78.8 mg per deciliter (2.04 mmol 
per liter) in the placebo group. The mean blood 
pressure at the end of the study was 132/77 mm Hg 
in the darapladib group and 131/77 mm Hg in 
the placebo group.
Efficacy Outcomes
Primary End Point
The primary end point occurred in 769 of 7924 
patients (9.7%) in the darapladib group and in 
819 of 7904 patients (10.4%) in the placebo group 
(hazard ratio in the darapladib group, 0.94; 95% 
CI, 0.85 to 1.03; P = 0.20) (Table 2 and Fig. 2). 
There were no significant effects of darapladib 
on any of the components of the primary end 
point (cardiovascular death, myocardial infarc-
tion, or stroke) or on all-cause mortality. The 
hazard ratio for the effect of darapladib on myo-
cardial infarction was 0.89 (95% CI, 0.77 to 1.03; 
P = 0.11). The effects on different types of myo-
cardial infarction are shown in the Table S2 in 
the Supplementary Appendix.
The treatment effect with respect to the pri-
mary end point was consistent in almost all pre-
specified subgroups. The only interactions below 
the P = 0.10 level were among smokers (P = 0.04 
Table 2. Primary and Secondary Efficacy End Points.*
End Point Placebo (N = 7904) Darapladib (N = 7924) Hazard Ratio (95% CI)† P Value
Patients  
with Events
Event  
Rate
Patients  
with Events
Event  
Rate
no. (%)
no. of events/ 
100 person-yr no. (%)
no. of events/ 
100 person-yr
Primary end point 819 (10.4) 3.04 769 (9.7) 2.85 0.94 (0.85–1.03) 0.20
Cardiovascular death 315 (4.0) 1.13 308 (3.9) 1.11
Nonfatal myocardial infarction 369 (4.7) 1.36 329 (4.2) 1.21
Nonfatal stroke 135 (1.7) 0.49 132 (1.7) 0.48
Secondary end point
Major coronary event 814 (10.3) 3.03 737 (9.3) 2.74 0.90 (0.82–1.00) 0.045
Death from coronary heart disease 303 (3.8) 1.09 284 (3.6) 1.02
Nonfatal myocardial infarction 368 (4.7) 1.36 325 (4.1) 1.20
Urgent coronary revascularization for 
myocardial ischemia
143 (1.8) 0.52 128 (1.6) 0.46
Total coronary events 1269 (16.1) 4.90 1159 (14.6) 4.45 0.91 (0.84–0.98) 0.02
Death from coronary heart disease 293 (3.7) 1.06 270 (3.4) 0.97
Nonfatal myocardial infarction 320 (4.0) 1.18 281 (3.5) 1.03
Hospitalization for unstable angina 145 (1.8) 0.53 129 (1.6) 0.47
Any coronary revascularization procedure 511 (6.5) 1.91 479 (6.0) 1.78
Cardiovascular death 373 (4.7) 1.34 359 (4.5) 1.29 0.96 (0.83–1.11) 0.59
Myocardial infarction 405 (5.1) 1.49 361 (4.6) 1.33 0.89 (0.77–1.03) 0.11
Stroke 152 (1.9) 0.55 154 (1.9) 0.56 1.01 (0.81–1.27) 0.92
All-cause mortality, nonfatal myocardial 
infarction, or nonfatal stroke
962 (12.2) 3.57 926 (11.7) 3.43 0.96 (0.88–1.05) 0.40
All-cause mortality 458 (5.8) 1.65 465 (5.9) 1.67
Nonfatal myocardial infarction 369 (4.7) 1.36 329 (4.2) 1.21
Nonfatal stroke 135 (1.7) 0.49 132 (1.7) 0.48
Total all-cause mortality 577 (7.3) 2.00 582 (7.3) 2.02 1.01 (0.90–1.13) 0.87
* The components of each of the composite end points have been summarized as mutually exclusive components without hazard ratios, 
 confidence intervals, or P values. A mutually exclusive component is the first occurrence of any event in the composite. All other categories 
represent time-to-event end points and are specified as primary or secondary end points in the protocol.
† Hazard ratios are for the darapladib group, as compared with the placebo group.
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for interaction) and white patients (P = 0.08 for 
interaction) (Fig. S2 in the Supplementary Ap-
pendix).
Secondary End Points
Among patients receiving darapladib, there was a 
nominally significant reduction in the first pre-
specified secondary end point of a composite of 
major coronary events, which occurred in 737 
patients (9.3%) in the darapladib group and in 
814 patients (10.3%) in the placebo group (haz-
ard ratio, 0.90; 95% CI, 0.82 to 1.00; P = 0.045) 
(Table 2, and Fig. S3 in the Supplementary Ap-
pendix). Similar effects were observed for the 
composite of total coronary events (hazard ratio, 
0.91; 95% CI, 0.84 to 0.98; P = 0.02).
Adverse Events
More patients in the darapladib group than in 
the placebo group discontinued the study drug 
(32.7% vs. 26.8%; hazard ratio, 1.29; 95% CI, 
1.22 to 1.37) (Fig. S4 in the Supplementary Ap-
pendix). Any adverse event leading to discon-
tinuation of a study drug occurred in 19.8% of 
the patients in the darapladib group and in 
13.5% of those in the placebo group (hazard 
ratio, 1.55; 95% CI, 1.43 to 1.67) (Table 3). More 
patients in the darapla dib group than in the pla-
cebo group discontinued the study drug because 
of diarrhea (3.2% vs. 0.8%), feces odor (2.2% vs. 
0.1%), urine odor (1.4% vs. <0.1%), and skin odor 
(2.2% vs. 0.1%).
There were more serious adverse events of 
renal failure in the darapladib group than in the 
placebo group (1.5% vs. 1.1%; hazard ratio, 1.35; 
95% CI, 1.03 to 1.78). At 3 months, the mean 
estimated GFR was lower by 2 ml per minute per 
1.73 m2 of body-surface area in the darapladib 
group than in the placebo group, with a similar 
between-group difference observed during the 
entire treatment period. There was no signifi-
cant between-group difference in the subgroup 
of 2650 patients in whom the estimated GFR 
was measured approximately 1 month after the 
end of treatment, with a change from baseline 
in the estimated GFR in the darapladib group, 
as compared with the placebo group, of −0.12 ml 
per minute per 1.73 m2 (95% CI, −1.35 to 1.12; 
P = 0.85). No significant between-group difference 
in the number of overall cancers or gastrointes-
tinal cancers was observed.
Discussion
In this large, multicenter, randomized trial involv-
ing patients with stable chronic coronary heart 
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Figure 2. Kaplan–Meier Curves for the Primary End Point of Death from Cardiovascular Causes, Myocardial Infarction, 
or Stroke.
The inset shows the same data on an enlarged y axis.
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disease who were followed for a median of 
3.7 years, darapladib did not significantly reduce 
the incidence of the primary end point of cardio-
vascular death, myocardial infarction, or stroke. 
There were no significant reductions in the inci-
dence of the components of the primary end 
point, as assessed individually, or in the rate of 
all-cause mortality. There was a nominally sig-
nificant reduction in the secondary end points of 
major and total coronary events, which is a sig-
nal of possible efficacy. The lack of effect of the 
administered dose of darapladib on the primary 
end point may relate to a smaller effect on vul-
nerable coronary plaque than was anticipated on 
the basis of previous studies.12,13
It is possible that the coronary risk among 
patients in our study may already have been 
minimized by concurrent therapy. The trial was 
designed to test the incremental effect of a new 
treatment administered in patients who were re-
ceiving a high level of standard of care for second-
ary prevention at baseline. Thus, more than a 
third of the patients had an LDL cholesterol 
level of less than 70 mg per deciliter (1.81 mmol 
per liter) at baseline, and revascularization had 
been performed in 75% of the patients before 
randomization. High rates of the use of evidence-
based medications were maintained throughout 
the trial. These standards of care are consis-
tently higher than those that were observed in 
patients with stable chronic coronary heart dis-
ease who were included in previous large inter-
national registries.16-18 These factors probably 
reduced event rates in the two study groups and 
may have reduced the proportion of events that 
were modifiable.
Another consideration is that 96% of the pa-
tients at trial closeout were taking statins, which 
have been shown to reduce levels of lipoprotein-
associated phospholipase A2 by up to 35%.19-21 
In addition, in the Long-Term Intervention with 
Pravastatin in Ischemic Disease (LIPID) study, 
among patients with stable chronic coronary 
heart disease, more than half the treatment ef-
fect of pravastatin in reducing rates of death 
from coronary heart disease or myocardial infarc-
tion was estimated to be due to an asso ciation 
with a reduction in levels of lipoprotein-associated 
phospholipase A2.22 Incremental benefits of in-
hibiting lipoprotein-associated phospholipase A2 
activity, if present, could be less in patients treated 
with statins.
There was a nominally significant reduction 
of approximately 10% in the rate of the pre-
specified secondary composite end points of 
major and total coronary events. The effects on 
these end points were consistent across the com-
ponents of these composite end points, includ-
ing death from coronary heart disease, myo-
cardial infarction, coronary revascularization, 
Table 3. Adverse Events.
Event
Placebo 
(N = 7890)
Darapladib  
(N = 7912)
no. of patients (%)
Any serious adverse event* 3448 (43.7) 3369 (42.6)
Any adverse event leading to study-drug 
discontinuation
1067 (13.5) 1569 (19.8)
Diarrhea
Any 495 (6.3) 965 (12.2)
Leading to study-drug discontinuation 60 (0.8) 254 (3.2)
Abnormal feces odor
Any 63 (0.8) 728 (9.2)
Leading to study-drug discontinuation 5 (0.1) 177 (2.2)
Abnormal skin odor
Any 34 (0.4) 383 (4.8)
Leading to study-drug discontinuation 4 (0.1) 174 (2.2)
Abnormal urine odor
Any 81 (1.0) 473 (6.0)
Leading to study-drug discontinuation 1 (<0.1) 113 (1.4)
Asthma 64 (0.8) 43 (0.5)
Renal failure† 89 (1.1) 120 (1.5)
Newly diagnosed cancer
Any 529 (6.7) 508 (6.4)
Adjudicated gastrointestinal 105 (1.3) 102 (1.3)
Liver events‡ 52 (0.7) 54 (0.7)
Anaphylaxis‡ 7 (0.1) 9 (0.1)
* Serious adverse events include cardiovascular events. A complete list of ad-
verse events according to system organ class is provided in Table S3 in the 
Supplementary Appendix.
† Patients listed in this category include all those with serious renal adverse events 
according to the Medical Dictionary for Regulatory Activities preferred terms of 
acute renal failure, renal failure, and chronic renal failure. The mean (±SD) 
change from baseline in the estimated glomerular filtration rate at the end of 
the treatment period was a reduction of 0.8±14.1 ml per minute per 1.73 m2 
among 7322 patients who were evaluated in the darapladib group and an in-
crease of 1.7±14.4 ml per minute per 1.73 m2 among 7498 patients who were 
evaluated in the placebo group, for a between-group difference (darapladib 
group minus placebo group) of −2.5 ml per minute per 1.73 m2 (95% confi-
dence interval, −3.0 to −2.1).
‡ All the patients included in this category met the criteria for discontinuing the 
study on the basis of these events, as specified in the protocol.
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and hospitalization for unstable angina, and it 
is possible that the inhibition of lipoprotein-
associated phospholipase A2 may reduce these 
measures of coronary disease risk. However, 
these findings should be considered exploratory 
and of uncertain importance in light of the lack 
of effect on the primary end point.
In accordance with previous findings, there 
was an increase in the rate of diarrhea among 
patients receiving darapladib, as compared 
with those receiving placebo, along with in-
creases in the rates of odor (in skin, feces, and 
urine), an effect that is thought to be related to 
the sulfhydryl group in the darapladib mole-
cule. Because of the occurrence of these events, 
there were more study-drug discontinuations in 
the darapladib group than in the placebo group, 
with most discontinuations occurring during 
the first year. The mechanisms and clinical 
significance of the changes in renal laboratory 
measures and of the renal serious adverse 
events are uncertain.
In conclusion, we evaluated a novel mecha-
nism for reducing plaque vulnerability by inhibi-
tion of lipoprotein-associated phospholipase A2 
with da rap la dib in patients with stable coronary 
heart disease who were receiving guideline-based 
background medical therapy. Darapladib did not 
significantly reduce the rate of the primary end 
point of cardiovascular death, myocardial infarc-
tion, or stroke.
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